Abstract 952P
Background
Transarterial chemoembolization (TACE) in combination with lenvatinib has been reported in several exploratory clinical studies in Chinese patients with hepatocellular carcinoma (HCC). Studies have showed good tumor response and survival benefit for combination therapy based on TACE plus lenvatinib in patients with advanced HCC. A multicenter, real-world study was conducted to explore the efficacy and safety of TACE in combination with lenvatinib as initial treatment for unresectable HCC patients in a real-world setting (PROLONG study, NCT04560751).
Methods
This real-world study was conducted at 7 centers in China. Eligible patients were aged more than 18 years old, with HCC, CNLC stage IIb-IIIb with unresectable diseases, Child-Pugh ≤7, Eastern Cooperative Oncology Group (ECOG) performance status 0-1, no prior systemic therapy. All patients received TACE combined with lenvatinib, with or without immune checkpoint inhibitors. The primary endpoint was objective response rate (ORR), which was evaluated according to mRECIST, and secondary endpoints included organ-specific objective response rate, progression-free survival (PFS), AFP response rate and time to progression (TTP).
Results
A total of 197 patients were enrolled from August 2020 to February 2023, with 145 patients evaluable for efficacy. The ORR was 48.3% evaluated according to mRECIST, with a complete response (CR) rate of 8.3%, partial response (PR) rate of 40%. The disease control rate (DCR) was 86.2%. The median PFS was 10.2 months (95%CI, 5.9-14.5), and the median OS has not been reached. The most common adverse events (AE) were fever, elevated transaminases, and decreased platelets. No treatment-related grade 5 AE occurred.
Conclusions
Combination therapy based on TACE plus lenvatinib in patients with unresectable hepatocellular carcinoma showed promising efficacy in the real-world setting. No unexpected adverse events were observed.
Clinical trial identification
NCT04560751.
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
990P - Prognosis prediction for unresectable hepatocellular carcinoma undergoing hepatic arterial infusion chemotherapy using convolutional neural network model
Presenter: bing quan
Session: Poster session 18
991P - Real-world comparison of trans-arterial chemoembolization and bland embolization for the treatment of hepatocellular carcinoma: A propensity score analysis
Presenter: Allan Ramos-Esquivel
Session: Poster session 18
993P - Thyroid dysfunction after atezolizumab and bevacizumab is associated with favorable outcomes in hepatocellular carcinoma (IMbrave150 and Korean patients cohorts)
Presenter: Hongjae Chon
Session: Poster session 18
995P - Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada
Presenter: Dominick Bossé
Session: Poster session 18
996P - Transarterial chemoembolization combined donafenib with/without programmed death-1 inhibitors for initially unresectable hepatocellular carcinoma in a multicenter retrospective study
Presenter: Xuhua Duan
Session: Poster session 18
998P - Efficacy and safety of curative hepatectomy after conversion therapies for initial unresectable hepatocellular carcinoma: A multicenter propensity score matching study
Presenter: Rong-yun Mai
Session: Poster session 18